Výsledky vyhľadávania - "nirsevimab"

Respiratory viruses in childhood: surveillance, analysis, and modelling of their epidemiological dynamics. The case of Catalonia.

Autori: Perramon Malavez, Aida

Prispievatelia: University/Department: Universitat Politècnica de Catalunya. Departament de Física

Thesis Advisors: Prats Soler, Clara, Soriano Arandes, Antoni

Zdroj: TDX (Tesis Doctorals en Xarxa)

Predmety: mathematical modelling, infectious diseases, RSV, influenza, SARS-CoV-2, nirsevimab, SEIR, Gompertz, paediatrics, epidemiology., modelització matemàtica, malalties infeccioses, pediatria, epidemiologia, modelización matemática, enfermedades infecciosas, VRS, pediatría, epidemiología, Àrees temàtiques de la UPC::Física, Àrees temàtiques de la UPC::Ciències de la salut, 577 - Bioquímica. Biologia molecular. Biofísica, 616. 2 - Patologia de l'aparell respiratori

Popis súboru: application/pdf

Prístupová URL adresa: http://hdl.handle.net/10803/695076
https://dx.doi.org/10.5821/dissertation-2117-439852

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department

Autori: Silva-Afonso, Raíssa de Fátima Platas-Abenza, Guillermo Guerrero-Soler, María a ďalší

Prispievatelia: Silva-Afonso, Raíssa de Fátima Platas-Abenza, Guillermo Guerrero-Soler, María a ďalší

Zdroj: RUA. Repositorio Institucional de la Universidad de Alicante
Universidad de Alicante (UA)

Predmety: Intervention program evaluation, Infecciones respiratorias agudas graves, Ecological study, Gripe, Evaluación de la efectividad de la vacuna COVID-19, Severe acute respiratory infections, Evaluation of influenza vaccine effectiveness, COVID-19, Respiratory syncytial virus, Temporada 2023-2024, Influenza, 2023–2024 season, Evaluation of COVID-19 vaccine effectiveness, Estudio ecológico, Evaluación del programa de intervención, Virus respiratorio sincitial, Evaluación de la efectividad de la inmunización con nirsevimab, Evaluation of immunization effectiveness with nirsevimab, Evaluación de la efectividad de la vacuna de la gripe

Prístupová URL adresa: http://hdl.handle.net/10045/154410
http://hdl.handle.net/10045/153861

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

Zdroj: A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVO (TM)), Infant Nirsevimab (BEYFORTUS (TM)) Immunization, or Both Products During the First Year of Life

A Clinical Trial of SIBP-A16 Injection in Healthy Adults

Zdroj: A Randomized, Double-blind, Placebo/Positive Control Phase Ia Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SIBP-A16 Injection in Healthy Adults

Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination (PIPELINE-RSV-F)

Zdroj: Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination: a Randomised Controlled Trial in France as Part of the Pregnancy and Infant PrEparedness pLatform IN Europe - PIPELINE

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

Zdroj: A Phase 4, Open-label, Single-arm Clinical Study to Describe Safety and Efficacy Outcomes Associated With the Use of Nirsevimab in Neonates and Infants Born During or Entering Their First Respiratory Syncytial Virus (RSV) Season and in Children up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Zdroj: BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

Safety of RSV Preventive Monoclonal Antibody

Autori: Centers for Disease Control and Prevention Children's Hospital Medical Center, Cincinnati Columbia University a ďalší

Zdroj: Safety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in Infants

A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

Zdroj: A Prospective, Single-arm, Non-interventional, Multi-center, Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

Autori: AstraZeneca

Zdroj: A Phase IIIb Randomized Open-label Study of Nirsevimab (Versus no Intervention) in Preventing Hospitalizations Due to Respiratory Syncytial Virus in Infants (HARMONIE)
Munro APS, Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Vassilouthis NC, Carreno M, Moreau C, Bourron P, Marcelon L, Mari K, Roberts M, Tissieres P, Royal S, Faust SN; HARMONIE Study Group. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissieres P, Royal S, Faust SN; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Autori: National Institute of Allergy and Infectious Diseases (NIAID)

Zdroj: Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Recommendation for immune prophylaxis of respiratory syncytial virus infection in children

Autori: Ping-Ing Lee Yhu-Chering Huang Chih-Jung Chen a ďalší

Zdroj: Journal of Microbiology, Immunology and Infection, Vol 58, Iss 3, Pp 288-293 (2025)

Predmety: monoclonal antibody, Prophylaxis, respiratory syncytial virus, palivizumab, nirsevimab, Microbiology, QR1-502

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40032543
https://doaj.org/article/3f5a52167ee1419daa148d1a344da883

Turkish pediatricians’ knowledge, attitudes, and awareness of respiratory syncytial virus (RSV) infection and immunization strategies: a cross-sectional study

Autori: İsmail Yıldız Erdem Gönüllü Sıla Yılmaz a ďalší

Zdroj: The Turkish Journal of Pediatrics, Vol 67, Iss 2 (2025)

Predmety: respiratory syncytial virus, pediatrician, immunization, nirsevimab, Pediatrics, RJ1-570

Prístupová URL adresa: https://doaj.org/article/4a808efa585241b4b50f8c31a911c591

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (CHIMES)

Autori: IQVIA RDS Inc.

Zdroj: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China

Other URLs: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination. (PIPELINE-RSV)

Zdroj: PIPELINE-RSV International Trial. Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)- RSV International Immunisation Adaptive Platform Trial.

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)

Autori: Iqvia Pty Ltd

Zdroj: A Phase III Single-Arm Open-Label Study to Evaluate the Safety PK ADA and Anti RSV nAb Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants With CHD, CLD, Immunocompromise, Down Syndrome, or Born Pre-Term in Japan

Other URLs: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort

Autori: Alexia Kieffer Mehdi Ghemmouri Samira Soudani a ďalší

Zdroj: Expert Review of Vaccines, Vol 24, Iss 1, Pp 1086-1098 (2025)

Predmety: Burden, infants, lower respiratory tract disease, nirsevimab, clesrovimab, RSV, RSVpreF, Internal medicine, RC31-1245

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1476-0584; https://doaj.org/toc/1744-8395

Prístupová URL adresa: https://doaj.org/article/f628f05a5a0a438ca4ace175f839d1b0

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan

Autori: Shinichi Noto Alexia Kieffer Samira Soudani a ďalší

Zdroj: Infect Dis Ther
Infectious Diseases and Therapy, Vol 14, Iss 4, Pp 847-865 (2025)

Predmety: Nirsevimab, Lower respiratory tract disease, RSV, Immunization, Burden, Infectious and parasitic diseases, RC109-216, Respiratory syncytial virus, Original Research

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40153134
https://doaj.org/article/f2e974a2ee734dcabfaef5c662ee565f

Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus‐Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns

Autori: Juan Manuel Rius‐Peris Enrique Palomo‐Atance Eva Muro‐Díaz a ďalší

Zdroj: ACTA PAEDIATRICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Instituto de Investigación Sanitaria La Fe (IIS La Fe)

Predmety: hospitalisation, respiratory syncytial virus, immunisation, bronchiolitis, nirsevimab

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40135713
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=22506

Global Pediatric Pulmonology Alliance recommendations to protect all infants against respiratory syncytial virus with prophylactic monoclonal antibodies

Autori: Kunling Shen Lance E. Rodewald Yonghong Yang a ďalší

Zdroj: Pediatr Investig
Pediatric Investigation, Vol 9, Iss 1, Pp 35-40 (2025)

Predmety: Monoclonal antibody, Nirsevimab, Infant, Respiratory syncytial virus, Acute lower respiratory tract infection, Pediatrics, RJ1-570, Position Paper and Recommendation

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40241887
https://doaj.org/article/1659d9ec668c4a91a03716ada767cd40